Nexthera Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Nexthera Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-396,198	Closed	-$7.74M	–	35
2018 Q4	$7.74M	Buy	+396,198	New	+$7.77M	3.19%	11
2017 Q1	–	Sell	-500,000	Closed	-$8.09M	–	53
2016 Q4	$8.09M	Buy	+500,000	New	+$9.07M	4.74%	7
2016 Q2	–	Sell	-220,000	Closed	-$3.65M	–	45
2016 Q1	$3.65M	Buy	220,000 +76,000	+53%	+$1.33M	3.78%	8
2015 Q4	$3.12M	Buy	+144,000	New	+$2.8M	4.43%	8

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nexthera Capital's HZNP Position: Q1 2019 in Review

Nexthera Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2019, closing a stake of 396,198 shares — an estimated $7.74M sold.

Nexthera Capital first reported a position in HZNP in Q4 2015 and held it in 4 quarters. The position peaked at $8.09M in Q4 2016. 297 funds tracked by Wall St. Rank hold HZNP as of Q1 2019.

Nexthera Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2019 after selling out during the quarter.
Nexthera Capital sold 396,198 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2019, an estimated $7.74M.
Nexthera Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 4 quarters.
Nexthera Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.09M in Q4 2016.
297 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2019.

Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.